These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33638275)

  • 1. Dosage strategies for delaying resistance emergence in heterogeneous tumors.
    Vakil V; Trappe W
    FEBS Open Bio; 2021 May; 11(5):1322-1331. PubMed ID: 33638275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive therapy.
    Gatenby RA; Silva AS; Gillies RJ; Frieden BR
    Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Resistant Cancer Treatment Strategies Based on the Dynamics of Clonal Evolution and PKPD Modeling of Drug Combinations.
    Vakil V; Trappe W
    IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(3):1603-1614. PubMed ID: 33326383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
    Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
    Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of resistance to anti-cancer therapy during general dosing schedules.
    Foo J; Michor F
    J Theor Biol; 2010 Mar; 263(2):179-88. PubMed ID: 20004211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy.
    Cho H; Levy D
    Bull Math Biol; 2017 Dec; 79(12):2986-3012. PubMed ID: 29022203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacological point of view of resistance to therapy in tumors.
    Damia G; Garattini S
    Cancer Treat Rev; 2014 Sep; 40(8):909-16. PubMed ID: 24969326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach.
    Ledzewicz U; Wang S; Schattler H; Andre N; Heng MA; Pasquier E
    Math Biosci Eng; 2017 Feb; 14(1):217-235. PubMed ID: 27879129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
    Cho H; Levy D
    J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitation of emergence of multidrug-resistant state by alteration of tumor environment: implications from competitive ecology models.
    Michelson S
    Cancer Treat Rep; 1987 Nov; 71(11):1093-4. PubMed ID: 3677116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance.
    Cassidy T; Nichol D; Robertson-Tessi M; Craig M; Anderson ARA
    PLoS Comput Biol; 2021 Aug; 17(8):e1009348. PubMed ID: 34460809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype- or Phenotype-Targeting Anticancer Therapies? Lessons from Tumor Evolutionary Biology.
    Escargueil AE; Prado S; Dezaire A; Clairambault J; Larsen AK; Soares DG
    Curr Pharm Des; 2016; 22(44):6625-6644. PubMed ID: 27587198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
    Sui H; Zhu L; Deng W; Li Q
    Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and prevention of resistance against small molecule inhibitors.
    Wodarz D; Komarova NL
    Semin Cancer Biol; 2005 Dec; 15(6):506-14. PubMed ID: 16154360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory.
    Zhang L; Ma J; Liu L; Li G; Li H; Hao Y; Zhang X; Ma X; Chen Y; Wu J; Wang X; Yang S; Xu S
    Crit Rev Oncol Hematol; 2023 Dec; 192():104192. PubMed ID: 37898477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor heterogeneity and drug resistance.
    Dexter DL; Leith JT
    J Clin Oncol; 1986 Feb; 4(2):244-57. PubMed ID: 3944607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prevention strategy for circumventing drug resistance in cancer chemotherapy.
    Frenkel GD; Caffrey PB
    Curr Pharm Des; 2001 Nov; 7(16):1595-614. PubMed ID: 11562301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.